Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

133%(4 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_2

25%

Ph phase_3

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

1(25.0%)

Phase 3Large-scale testing

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (25.0%)

Phase 33 (75.0%)

Trials by Status

completed375%

terminated125%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_2

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227

completedphase_3

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

NCT00079677

completedphase_3

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

NCT00078325

completedphase_3

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

NCT00080288

Clinical Trials (4)

Showing 4 of 4 trials

NCT00825227Phase 2

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

Terminated

NCT00079677Phase 3

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome

Completed

NCT00078325Phase 3

Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)

Completed

NCT00080288Phase 3

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4